Charles River Laboratories International Balans Gezondheid
Financiële gezondheid criteriumcontroles 4/6
Charles River Laboratories International heeft een totaal eigen vermogen van $3.8B en een totale schuld van $2.4B, wat de schuld-eigenvermogensverhouding op 63.2% brengt. De totale activa en totale passiva bedragen respectievelijk $7.9B en $4.2B. De EBIT Charles River Laboratories International is $628.1M waardoor de rentedekking 5 is. Het heeft contanten en kortetermijnbeleggingen van $179.2M.
Belangrijke informatie
63.2%
Verhouding schuld/eigen vermogen
US$2.38b
Schuld
| Rente dekkingsratio | 5x |
| Contant | US$179.21m |
| Aandelen | US$3.77b |
| Totaal verplichtingen | US$4.18b |
| Totaal activa | US$7.95b |
Recente financiële gezondheidsupdates
Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 26
Charles River Laboratories International (NYSE:CRL) Takes On Some Risk With Its Use Of Debt
Jul 26Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Mar 27Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 27Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly
Jul 03These 4 Measures Indicate That Charles River Laboratories International (NYSE:CRL) Is Using Debt Reasonably Well
Apr 02Recent updates
Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 26What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You
Oct 11Why Charles River Laboratories International, Inc. (NYSE:CRL) Could Be Worth Watching
Sep 10US$227: That's What Analysts Think Charles River Laboratories International, Inc. (NYSE:CRL) Is Worth After Its Latest Results
Aug 10Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)
Aug 10Charles River Laboratories International (NYSE:CRL) Takes On Some Risk With Its Use Of Debt
Jul 26Risks To Shareholder Returns Are Elevated At These Prices For Charles River Laboratories International, Inc. (NYSE:CRL)
Jul 11Charles River Laboratories: Fair Valuation Against Fundamentals
May 31What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?
May 25Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 30% Discount?
Apr 27Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings
Apr 11Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Mar 27Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues
Feb 21Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'
Feb 16Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?
Jan 17Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up
Jan 02Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth
Dec 17Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation
Nov 26Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?
Nov 12Charles River: Q3 Points To Ongoing Deterioration
Nov 09Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 27At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?
Oct 12Charles River Laboratories: Diving Into The Lab (Rating Upgrade)
Oct 06Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?
Aug 10Charles River Laboratories: Very Attractive After The Pullback
Jul 26Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?
Jul 22Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly
Jul 03When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?
Jun 19A Look At The Intrinsic Value Of Charles River Laboratories International, Inc. (NYSE:CRL)
May 01Should You Be Adding Charles River Laboratories International (NYSE:CRL) To Your Watchlist Today?
Apr 16These 4 Measures Indicate That Charles River Laboratories International (NYSE:CRL) Is Using Debt Reasonably Well
Apr 02Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?
Mar 19Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $1.5B ) CRL } overtreffen de korte termijn passiva ( $947.5M ).
Langlopende schulden: De kortetermijnactiva van CRL ( $1.5B ) dekken de langetermijnschulden ( $3.2B ) niet.
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: De netto schuld/eigen vermogen ratio ( 58.4% ) CRL wordt als hoog beschouwd.
Schuld verminderen: De schuld/eigen vermogen-ratio van CRL is de afgelopen 5 jaar gedaald van 138.1% naar 63.2%.
Schuldendekking: De schuld van CRL wordt goed gedekt door de operationele kasstroom ( 31.5% ).
Rentedekking: De rentebetalingen op de schuld van CRL worden goed gedekt door EBIT ( 5 x dekking).